PID - PowerShares Intl Div Achiev ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
16.22
-0.04 (-0.25%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.26
Open16.30
Bid0.00 x 0
Ask0.00 x 0
Day's Range16.22 - 16.44
52 Week Range14.54 - 17.38
Volume182,881
Avg. Volume205,391
Net Assets942.97M
NAV17.02
PE Ratio (TTM)N/A
Yield3.36%
YTD Return2.84%
Beta (3y)1.01
Expense Ratio (net)0.56%
Inception Date2005-09-15
Trade prices are not sourced from all markets
  • How Wall Street Reacted to Berkshire Hathaway Investment in Teva
    Market Realist6 days ago

    How Wall Street Reacted to Berkshire Hathaway Investment in Teva

    After Berkshire Hathaway (BRK) disclosed its investment of $358 million in Teva Pharmaceuticals (TEVA) on February 14, 2018, in a regulatory filing at the end of 4Q17, Wall Street analysts have had a lot to say about the investment. Teva Pharmaceuticals stock rose ~10.5% during the morning of February 15, 2018, before closing at a rise of ~7.7% on the day. The PowerShares International Dividend Achievers Portfolio (PID) rose ~1.3% on February 15, 2018.

  • Analysts’ Updates after Sanofi’s Bioverativ Announcement
    Market Realist14 days ago

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    Sanofi (SNY) announced its acquisitions of Bioverativ and Ablynx in the last week of January 2018. The Bioverativ acquisition is valued at more than $11.6 billion, while the Ablynx acquisition is worth 3.9 billion euros. In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

  • Exploring Bioverativ’s Business Profile and Market Presence
    Market Realist15 days ago

    Exploring Bioverativ’s Business Profile and Market Presence

    Sanofi Advances Its Blood Disorder Portfolio with 2 Acquisitions

  • PBA’s Dividends: Key Drivers
    Market Realist15 days ago

    PBA’s Dividends: Key Drivers

    The Top Annual Dividend-Growing Oil Stocks

  • What Could Continue to Drive ENB’s Dividends
    Market Realist15 days ago

    What Could Continue to Drive ENB’s Dividends

    Enbridge (ENB) is involved in energy transportation in the United States and Canada. Transportation and other services drove the growth in 2016, offset by commodity sales and gas distribution sales. All of these segments fueled growth in 9M17. The Liquids Pipelines, Green Power, and Transmission segments drove growth in 2016, offset by Gas Distribution, Gas Pipelines, and Processing and Energy Services.

  • Reuters16 days ago

    Dividend plays on slippery ground as bond yields steepen

    By Rushil Dutta (Reuters) - After a decade of easy-money policy that cut bond yields to almost nothing and lifted U.S. stock markets to records, companies that pay big dividends now look among the most ...

  • Novartis’s 4Q17 Earnings: Sandoz Business
    Market Realist17 days ago

    Novartis’s 4Q17 Earnings: Sandoz Business

    Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings

  • How Sanofi Can Benefit from Ablynx Acquisition
    Market Realist20 days ago

    How Sanofi Can Benefit from Ablynx Acquisition

    On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx including American depositary shares (or ADSs), warrants, and convertible bonds. Sanofi will acquire Ablynx by purchasing Albynx’s share at a price of 45 euros per share in cash, which is equivalent to an equity value of approximately 3.9 billion euros. Ablynx is a biopharmaceutical company that specializes in the development of Nanobodies.

  • How Is Novartis’s Subsidiary Sandoz Positioned for 2018?
    Market Realist27 days ago

    How Is Novartis’s Subsidiary Sandoz Positioned for 2018?

    How Novartis Is Positioned for 2018

  • Behind Novartis’s 4Q17 Estimates: Innovative Medicines
    Market Realistlast month

    Behind Novartis’s 4Q17 Estimates: Innovative Medicines

    Novartis’s (NVS) Innovative Medicines segment includes cardio-metabolic products, oncology products, immunology and dermatology products, respiratory products, neuroscience products, and established products. The segment’s contribution is ~67% of NVS’s total revenues.

  • Market Realist3 months ago

    Behind Sanofi’s 3Q17 Revenue Growth

    Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.

  • The Zacks Analyst Blog Highlights: SDIV, DWX, LVL, FGD and PID
    Zacks5 months ago

    The Zacks Analyst Blog Highlights: SDIV, DWX, LVL, FGD and PID

    The Zacks Analyst Blog Highlights: SDIV, DWX, LVL, FGD and PID

  • Market Realist5 months ago

    How TEVA’s CNS Drugs Performed in 1H17

    In 1H17, Teva Pharmaceutical's (TEVA) CNS (central nervous system) business generated revenues of ~$2.3 billion, or ~16% lower YoY (year-over-year).

  • 5 Hot Global Dividend ETFs
    Zacks5 months ago

    5 Hot Global Dividend ETFs

    Bond yields are creeping up. Brace yourselves with these high-dividend ETFs.

  • Market Realist5 months ago

    How TEVA’s Generic Medicines Franchise Is Positioned after 1H17

    In 1H17, Teva Pharmaceutical's (TEVA) generic medicines business generated revenues of ~$6.1 billion, or ~22% higher YoY (year-over-year).

  • Market Realist5 months ago

    How ONEOK Has Managed Its Impressive Dividend Yield

    ONEOK (OKE), the general partner and 41% owner of ONEOK Partners, owns one of the country’s premier natural gas liquid systems. The company’s revenue grew 15% in 2016 after falling…

  • Market Realist6 months ago

    What Happened to Novartis’s Innovative Medicines Business in 2Q17?

    Novartis's Innovative Medicines segment contributed over 67% of NVS's total revenues at nearly $8.3 billion for the quarter.

  • Global Dividend Payments Upbeat in Q2: ETFs to Benefit
    Zacks6 months ago

    Global Dividend Payments Upbeat in Q2: ETFs to Benefit

    Q2 global dividend payments were the healthiest quarterly performance since late 2015 and put these ETFs in focus.

  • Market Realist6 months ago

    Dividend Yield of Stanley Black & Decker

    Stanley Black & Decker's (SWK) PE ratio of 21.1x is pitted against a sector average of 29.3x. The dividend yield of 1.8% is pitted against a sector average of 1.6%.

  • Market Realist6 months ago

    A Look at Sanofi Pasteur’s Performance in 2Q17

    Sanofi Pasteur, Sanofi’s (SNY) human vaccine business, reported 26.2% revenue growth at constant exchange rates to 1.0 billion euros in 2Q17. Sanofi Pasteur reported growth across all product franchises ...

  • Market Realist6 months ago

    North America: Fresenius Medical Care’s Major Target Market in 2017

    In 2Q17, Fresenius Medical Care (FMS) reported revenues close to 3.3 billion euros, which represents year-over-year growth of ~11%.

  • Market Realist6 months ago

    Sanofi Genzyme Continues Driving Revenue Growth in 2Q17

    In 2Q17, Sanofi Genzyme (SNY) reported revenue growth of 13.5% to 1.7 billion euros. Considering a constant structure and constant exchange rates, the growth was 14.4%. Sanofi Genzyme, which includes product ...

  • Market Realist6 months ago

    Kimberly-Clark’s Dividend Growth

    Kimberly-Clark’s (KMB) 2016 net sales fell 2.0% due to declines in every segment.

  • Market Realist7 months ago

    Novartis in 2Q17: Performance of Sandoz

    Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16.

  • Market Realist7 months ago

    Analysts Expect Novartis’s Revenues to Fall in 2Q17

    Analysts expect Novartis's (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.